Sign up
Pharma Capital
EPIC: ZYNE
Market: NASDAQ
52-week High/Low: $24.57 / $5.42
Sector: Pharma & Biotech
Market Cap: $143.21M
Website:

At Zynerba Pharmaceuticals, we are dedicated to developing next-generation synthetic cannabinoid therapeutics for transdermal delivery for patients with high unmet medical needs.
Our mission is to improve the lives of patients battling severe health conditions including epilepsy, Fragile X syndrome, osteoarthritis, fibromyalgia and peripheral neuropathic pain through these therapeutics.
...

Zynerba Pharmaceuticals

Interactive graph

col 3
col 4
col 5
col 6
View full ZYNE profile View Profile
View All

© biotech Capital 2018

Biotech Capital, a subsidiary of Proactive Investors, acts as the vanguard for listed biotech companies to interact with institutional and highly capitalised investors.
Headquartered in London, Biotech Capital is led by a team of Europe's leading analysts and journalists, publishing daily content, covering all key movements in the Biotechnology market.